Blood reviews · 2025
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pagliuca Simona, Malard Florent, Mooyaart Jarl E, Daskalakis Michael, Gabellier Ludovic, Yakoub-Agha Ibrahim, Ram Ron, Besley Caroline, Forcade Edouard, Vucinic Vladan, Corral Lucía López, Vydra Jan, von Tresckow Bastian, Amat Paula, Amrolia Persis, Vandenberghe Peter, Stölzel Friedrich, Sica Simona, Rubio Marie Thérèse, Hoogenboom Jorinde D, Ortiz-Maldonado Valentín, Nagler Arnon, Kuball Jürgen, Chabannon Christian, Ruggeri Annalisa
Аннотация
Immune monitoring of cell therapies is a complex and evolving topic, particularly in the rapid expanding field of chimeric antigen receptor T (CAR-T) cell applications. Defining essential, recommended, and optional immune monitoring data post-CAR-T cell infusion is crucial to improve patient outcomes and inform post-treatment decisions. To address this gap, we conducted a survey-based study across centers affiliated with the European Society for Blood and Marrow Transplantation (EBMT), focusing on patients treated with European Medicines Agency (EMA)-approved CAR-T products. Building on a thorough review of the literature, we mapped the current landscape of immune monitoring practices and assessed their impact on clinical management. By defining the state of the art in the field, this work marks an initial step towards a structured harmonization process potentially able to enhance the management and outcomes of patients undergoing these immune cell therapies.